Literature DB >> 24269190

One-step generation of different immunodeficient mice with multiple gene modifications by CRISPR/Cas9 mediated genome engineering.

Jiankui Zhou1, Bin Shen1, Wensheng Zhang2, Jianying Wang1, Jing Yang1, Li Chen1, Na Zhang3, Kai Zhu3, Juan Xu1, Bian Hu1, Qibin Leng4, Xingxu Huang5.   

Abstract

Taking advantage of the multiplexable genome engineering feature of the CRISPR/Cas9 system, we sought to generate different kinds of immunodeficient mouse strains by embryo co-microinjection of Cas9 mRNA and multiple sgRNAs targeting mouse B2m, Il2rg, Prf1, Prkdc, and Rag1. We successfully achieved multiple gene modifications, fragment deletion, double knockout of genes localizing on the same chromosome, and got different kinds of immunodeficient mouse models with different heritable genetic modifications at once, providing a one-step strategy for generating different immunodeficient mice which represents significant time-, labor-, and money-saving advantages over traditional approaches. Meanwhile, we improved the technology by optimizing the concentration of Cas9 and sgRNAs and designing two adjacent sgRNAs targeting one exon for each gene, which greatly increased the targeting efficiency and bi-allelic mutations.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cas9; Gene targeting; Immunodeficient; Mouse; Multiple

Mesh:

Substances:

Year:  2013        PMID: 24269190     DOI: 10.1016/j.biocel.2013.10.010

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  51 in total

Review 1.  iPSC-based drug screening for Huntington's disease.

Authors:  Ningzhe Zhang; Barbara J Bailus; Karen L Ring; Lisa M Ellerby
Journal:  Brain Res       Date:  2015-09-30       Impact factor: 3.252

Review 2.  From hacking the human genome to editing organs.

Authors:  Takamasa Tobita; Jorge Guzman-Lepe; Alexandra Collin de l'Hortet
Journal:  Organogenesis       Date:  2015-11-20       Impact factor: 2.500

3.  Leveraging premalignant biology for immune-based cancer prevention.

Authors:  Avrum Spira; Mary L Disis; John T Schiller; Eduardo Vilar; Timothy R Rebbeck; Rafael Bejar; Trey Ideker; Janine Arts; Matthew B Yurgelun; Jill P Mesirov; Anjana Rao; Judy Garber; Elizabeth M Jaffee; Scott M Lippman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-16       Impact factor: 11.205

4.  Genetic removal of the CH1 exon leads to the production of hypofunctional heavy chain-only IgG2a in rats.

Authors:  Zhenrong Li; Ming Zhang; Shunan Zheng; Yu Song; Xueqian Cheng; Di Yu; Lijuan Du; Liming Ren; Haitang Han; Yaofeng Zhao
Journal:  Transgenic Res       Date:  2020-02-20       Impact factor: 2.788

5.  CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein.

Authors:  Lichun Tang; Yanting Zeng; Hongzi Du; Mengmeng Gong; Jin Peng; Buxi Zhang; Ming Lei; Fang Zhao; Weihua Wang; Xiaowei Li; Jianqiao Liu
Journal:  Mol Genet Genomics       Date:  2017-03-01       Impact factor: 3.291

6.  Mosaicism diminishes the value of pre-implantation embryo biopsies for detecting CRISPR/Cas9 induced mutations in sheep.

Authors:  Marcela Vilarino; Fabian Patrik Suchy; Sheikh Tamir Rashid; Helen Lindsay; Juan Reyes; Bret Roberts McNabb; Talitha van der Meulen; Mark O Huising; Hiromitsu Nakauchi; Pablo Juan Ross
Journal:  Transgenic Res       Date:  2018-10-03       Impact factor: 2.788

7.  CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.

Authors:  Cong Huai; Chenqiang Jia; Ruilin Sun; Peipei Xu; Taishan Min; Qihan Wang; Chengde Zheng; Hongyan Chen; Daru Lu
Journal:  Hum Genet       Date:  2017-05-15       Impact factor: 4.132

Review 8.  Messenger RNA Delivery for Tissue Engineering and Regenerative Medicine Applications.

Authors:  Siddharth Patel; Avathamsa Athirasala; Paula P Menezes; N Ashwanikumar; Ting Zou; Gaurav Sahay; Luiz E Bertassoni
Journal:  Tissue Eng Part A       Date:  2018-06-07       Impact factor: 3.845

Review 9.  The new CRISPR-Cas system: RNA-guided genome engineering to efficiently produce any desired genetic alteration in animals.

Authors:  Davide Seruggia; Lluis Montoliu
Journal:  Transgenic Res       Date:  2014-08-06       Impact factor: 2.788

10.  BTG4 is a meiotic cell cycle-coupled maternal-zygotic-transition licensing factor in oocytes.

Authors:  Chao Yu; Shu-Yan Ji; Qian-Qian Sha; Yujiao Dang; Jian-Jie Zhou; Yin-Li Zhang; Yang Liu; Zhong-Wei Wang; Boqiang Hu; Qing-Yuan Sun; Shao-Chen Sun; Fuchou Tang; Heng-Yu Fan
Journal:  Nat Struct Mol Biol       Date:  2016-04-11       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.